PTEN and CD146 expression in endometrioid adenocarcinoma

Objective: Endometrioid adenocarcinoma is the most common pathological type of endometrial carcinoma. This study aimed to examine the expression of PTEN and CD146 in endometrioid adenocarcinoma, and to investigate their relationship with clinical characteristics of endometrioid adenocarcinoma. Materials and Methods: The expression of PTEN and CD146 in 126 specimens of endometrioid adenocarcinoma was detected by immunohistochemical technique, and the correlation of their expression with clinical parameters of the patients was analyzed. Results: PTEN expression in endometrioid adenocarcinoma group was lower than that in endometrial hyperplasia group and endometrial polyp group, while CD146 expression in endometrioid adenocarcinoma group was higher than that in endometrial hyperplasia group and endometrial polyp group (p < 0.05). High expression of CD146 was associated with his tological grade and depth of invasion of endometrioid adenocarcinoma, but there was no correlation between PTEN expression and clinical parameters. Conclusions: CD146 and PTEN may be promising biomarkers and targets for the diagnosis and treatment of endometrioid adenocarcinoma.

Endometrioid adenocarcinoma; PTEN; CD146; Pathology

[1] Morice P., Leary A., Creutzberg C., Abu-Rustum N., Darai E.: “Endometrial cancer”. Lancet, 2016, 387, 1094.

[2] Hakim S.A., Raboh N.M.: “Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters”. Int. J. Clin. Exp. Pathol., 2015, 8, 13225.

[3] Wang Y., Mang M., Wang Y., Wang L., Klein R., Kong B., Zheng W.: “Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma”. Am. J. Cancer Res., 2015, 5, 869.

[4] Makker A., Goel M.M.: “Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update”. Endocr. Relat. Cancer, 2016, 23, R85.

[5] Arik D., Kabukcuoglu S.: “CDX2 expression in endometrial endometrioid adenocarcinoma”. Eur. J. Gynaecol. Oncol., 2017, 38, 704.

[6] Silva J.L., Paulino E., Dias M.F., Melo A.C.: “Endometrial cancer: redefining the molecular-targeted approach”. Cancer Chemother. Pharmacol., 2015, 76, 1.

[7] Lei X., Guan C.W., Song Y., Wang H.: “The multifaceted role of CD146/MCAM in the promotion of melanoma progression”. Cancer Cell Int., 2015, 15, 3.

[8] Jiang G., Zhang L., Zhu Q., Bai D., Zhang C., Wang X.: “CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma”. J. Exp. Clin. Cancer Res., 2016, 35, 38.

[9] Jouve N., Bachelier R., Despoix N., Blin M.G., Matinzadeh M.K., Poitevin S., et al.: “CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation. Int J Cancer 2015; 137: 50- 60.

[10] Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer”. Anal. Cell Pathol., 2003, 25, 77.

[11] Latta E., Chapman W.B.: “PTEN mutations and evolving concepts in endometrial neoplasia”. Curr. Opin. Obstet. Gynecol., 2002, 14, 59.

[12] Yang M.F., Lou Y.L., Liu S.S., Wang S.S., Yin C.H., Cheng X.H., Huang O.P.: “Capn4 overexpression indicates poor prognosis of ovarian cancer patients”. J. Cancer, 2018, 9, 304.

[13] Correa D., Somoza R.A., Lin P., Schiemann W.P., Caplan A.I.: “Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche”. Int. J. Cancer, 2016, 138, 417.

[14] Najjar F., Al-Massarani G., Banat I., Alammar M.: “Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy”. Int. J. Biol. Markers, 2015, 30, e374.

[15] Wang Z., Yan X.: “CD146, a multi-functional molecule beyond adhesion”. Cancer Lett., 2013, 330, 150.

[16] Westrøm S., Bønsdorff T.B., Abbas N., Bruland Ø.S., Jonasdottir T.J., Mælandsmo G.M., Larsen R.H.: “Evaluation of CD146 as target for radioimmunotherapy against osteosarcoma”. PLoS One, 2016, 11, 0165382.